Pediatric brain tumors
YT Udaka, RJ Packer - Neurologic clinics, 2018 - neurologic.theclinics.com
Pediatric central nervous system (CNS) tumors are the second most common childhood
malignancy and the most common solid tumor in children. The incidence rate of childhood …
malignancy and the most common solid tumor in children. The incidence rate of childhood …
Molecular subgroups of medulloblastoma
Recent efforts at stratifying medulloblastomas based on their molecular features have
revolutionized our understanding of this morbidity. Collective efforts by multiple independent …
revolutionized our understanding of this morbidity. Collective efforts by multiple independent …
Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition
Smoothened (SMO) inhibitors recently entered clinical trials for sonic-hedgehog-driven
medulloblastoma (SHH-MB). Clinical response is highly variable. To understand the …
medulloblastoma (SHH-MB). Clinical response is highly variable. To understand the …
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 …
Medulloblastoma is the most common malignant brain tumor in childhood. Molecular studies
from several groups around the world demonstrated that medulloblastoma is not one …
from several groups around the world demonstrated that medulloblastoma is not one …
Circular extrachromosomal DNA promotes tumor heterogeneity in high-risk medulloblastoma
Circular extrachromosomal DNA (ecDNA) in patient tumors is an important driver of
oncogenic gene expression, evolution of drug resistance and poor patient outcomes …
oncogenic gene expression, evolution of drug resistance and poor patient outcomes …
Cytogenetic prognostication within medulloblastoma subgroups
Purpose Medulloblastoma comprises four distinct molecular subgroups: WNT, SHH, Group
3, and Group 4. Current medulloblastoma protocols stratify patients based on clinical …
3, and Group 4. Current medulloblastoma protocols stratify patients based on clinical …
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease
We undertook a comprehensive clinical and biological investigation of serial
medulloblastoma biopsies obtained at diagnosis and relapse. Combined MYC family …
medulloblastoma biopsies obtained at diagnosis and relapse. Combined MYC family …
Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development
Medulloblastoma is currently subclassified into distinct DNA methylation
subgroups/subtypes with particular clinico-molecular features. Using RNA sequencing (RNA …
subgroups/subtypes with particular clinico-molecular features. Using RNA sequencing (RNA …
Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study
M Sabel, G Fleischhack, S Tippelt, G Gustafsson… - Journal of neuro …, 2016 - Springer
Abstract The HIT-SIOP-PNET4 randomised trial for standard risk medulloblastoma
(MB)(2001–2006) included 338 patients and compared hyperfractionated and conventional …
(MB)(2001–2006) included 338 patients and compared hyperfractionated and conventional …
DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies
Molecular subclassification is rapidly informing the clinical management of
medulloblastoma. However, the disease remains associated with poor outcomes and …
medulloblastoma. However, the disease remains associated with poor outcomes and …